ALXO: ALX2004 and evorpacept advance toward registrational trials, targeting key oncology indications
ALX2004 is advancing through dose escalation with promising safety and activity signals, aiming for expansion and registrational studies next year. Evorpacept shows strong efficacy in CD47-high breast cancer patients, with robust enrollment and a clear path to phase III. Both programs are funded th…